The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I and pharmacokinetic (PK) study of continuous daily administration of P1446A-05, a potent and specific oral Cdk4 inhibitor.
Desiree Hao
Research Funding - Primal Healthcare Limited
Quincy Chu
Research Funding - Piramal Healthcare Limited
Stephen Welch
Research Funding - Piramal Healthcare Limited
Cindy Y. F. Yau
Research Funding - Ozmosis Research
Jennifer L. Spratlin
Research Funding - Piramal Healthcare Limited
Patricia Tang
Research Funding - Piramal Healthcare Limited
Mary J. MacKenzie
Research Funding - Piramal Healthcare Limited
Carol A. Townsley
Research Funding - Ozmosis Research
Diane Arndt
Research Funding - Piramal Healthcare Limited
Laureen Johnson
Research Funding - Piramal Healthcare Limited
Daniela Trapsa
Research Funding - Piramal Healthcare Limited
Pamela Degendorfer
Research Funding - Ozmosis Research
Sujay Kulkarni
Employment or Leadership Position - Piramal Healthcare Limited
Stock Ownership - Piramal Healthcare Limited
Gajendra Jawlekar
Employment or Leadership Position - Piramal Healthcare Limited
Poornima Dhobe
Employment or Leadership Position - Piramal Healthcare Limited
Amit M. Oza
Employment or Leadership Position - Ozmosis Research (U)
Research Funding - Ozmosis Research